0001541157-15-000002.txt : 20150928 0001541157-15-000002.hdr.sgml : 20150928 20150928135444 ACCESSION NUMBER: 0001541157-15-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20150928 DATE AS OF CHANGE: 20150928 EFFECTIVENESS DATE: 20150928 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akari Therapeutics Plc CENTRAL INDEX KEY: 0001541157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981034922 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-248315 FILM NUMBER: 151126952 BUSINESS ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (646) 350-0702 MAIL ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Celsus Therapeutics Plc. DATE OF NAME CHANGE: 20130621 FORMER COMPANY: FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC DATE OF NAME CHANGE: 20120201 D 1 primary_doc.xml X0707 D LIVE 0001541157 Akari Therapeutics Plc The Gridiron Building, One Pancras Squar C/O Pearl Cohen Zedek Latzer Baratz UK L London X0 UNITED KINGDOM N1C 4AG +44-203-318-3004 UNITED KINGDOM Celsus Therapeutics Plc. Morria Biopharmaceuticals PLC Corporation true Gur Roshwalb c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Executive Officer Director Dov Elefant c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Executive Officer Clive Richardson c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Executive Officer Director Mark Cohen c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Director Ray Prudo c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Director Allan Shaw c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Director Stuart Ungar c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Director James Hill c/o Akari Therapeutics Plc The Gridiron Building, One Pancras Squar London X0 UNITED KINGDOM N1C 4AG Director Biotechnology Decline to Disclose 06b false 2015-09-18 false true true Private placement consummated following closing of acquisition. 0 MTS Securities, LLC 104059 None None 623 Fifth Avenue 14th floor New York NY NEW YORK 10022 CA CALIFORNIA CT CONNECTICUT DE DELAWARE IL ILLINOIS MD MARYLAND MA MASSACHUSETTS NY NEW YORK TX TEXAS false Citigroup Global Markets Inc. 7059 None None 388 Greenwich Street New York NY NEW YORK 10013 CA CALIFORNIA CT CONNECTICUT DE DELAWARE IL ILLINOIS MD MARYLAND MA MASSACHUSETTS NY NEW YORK TX TEXAS false 75000000 75000000 0 false 28 5250000 0 Placement agent fees paid to MTS Securities, LLC and Citigroup Global Markets Inc. 0 false Akari Therapeutics Plc /s/ Gur Roshwalb Gur Roshwalb Chief Executive Officer and Director 2015-09-28